(Q30444706)

21 June 2017

1 reference

title

Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics (English)

1 reference

21 June 2017

0 references

1 reference

Susan C Modesitt

1

1 reference

21 June 2017

Amir A Jazaeri

series ordinal

2

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

21 June 2017

published in

1 reference

21 June 2017

volume

8

1 reference

21 June 2017

issue

14

1 reference

21 June 2017

page(s)

2293-2305

1 reference

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

FDG-PET for management of cervical and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

The impact of PET/CT in the management of recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Hormonal therapy in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Monoclonal antibody therapy of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

TLK-286: a novel glutathione S-transferase-activated prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phenoxodiol – an isoflavone analog – induces apoptosis in chemoresistant ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phenoxodiol offers hope for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Radical surgical procedure improves survival time in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2293

10.1517/14656566.8.14.2293

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference